More articles from Clinical studies

You have access
Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
YEN-HAO CHEN, YEN-YANG CHEN, JING-HOUNG WANG and CHAO-HUNG HUNG

Anticancer Research March 2023, 43 (3) 1377-1384; DOI: https://doi.org/10.21873/anticanres.16286
Open Access
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
MARINA ABE, TADAHIRO SHOJI, YOHEI CHIBA, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, FUMIAKI TAKAHASHI, TAKESHI AIDA and TSUKASA BABA

Anticancer Research March 2023, 43 (3) 1265-1272; DOI: https://doi.org/10.21873/anticanres.16273
Open Access
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
SANDRO M. WAGNER, TERESA MAGNES, THOMAS MELCHARDT, DOMINIK KIEM, LUKAS WEISS, DANIEL NEUREITER, CHRISTINA WAGNER, MARIE-BERNADETTE ARETIN, STEFAN NEMEC, GABRIELE GAMERITH, GEORG PALL, RICHARD GREIL and THORSTEN FUEREDER

Anticancer Research March 2023, 43 (3) 1273-1282; DOI: https://doi.org/10.21873/anticanres.16274
You have access
Impact of Concomitant Use of Azoles on Bortezomib-related Adverse Drug Reactions Using JADER
TAKUYA IMATOH, TAICHI MATSUMOTO, YUTAKA HARAMAKI and KEISUKE MIGITA

Anticancer Research March 2023, 43 (3) 1341-1349; DOI: https://doi.org/10.21873/anticanres.16282
You have access
Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
AKIHIRO TAMIYA, MOTOHIRO TAMIYA, YUJI INAGAKI, YOSHIHIKO TANIGUCHI, KEIKO NAKAO, YOSHINOBU MATSUDA, TAKAHISA KAWAMURA, KEI KUNIMASA, TAKAKO INOUE, KAZUMI NISHINO and KYOICHI OKISHIO

Anticancer Research March 2023, 43 (3) 1325-1330; DOI: https://doi.org/10.21873/anticanres.16280
You have access
Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?
RYUNOSUKE NAKAGAWA, HIROAKI IWAMOTO, RENATO NAITO, SUGURU KADOMOTO, HIROSHI YAEGASHI, SHOHEI KAWAGUCHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI, YOSHIFUMI KADONO and ATSUSHI MIZOKAMI

Anticancer Research March 2023, 43 (3) 1351-1359; DOI: https://doi.org/10.21873/anticanres.16283
You have access
Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data
VITTORIO GEBBIA, FEDERICA MARTORANA, MARIA VITA SANÒ, MARIA ROSARIA VALERIO, FRANCESCO GIOTTA, MASSIMILIANO SPADA, DARIO PIAZZA, MICHELE CARUSO and PAOLO VIGNERI

Anticancer Research March 2023, 43 (3) 1291-1299; DOI: https://doi.org/10.21873/anticanres.16276
You have access
Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18)
AKIMITSU MAEDA, HITOSHI ANDO, KEI IRIE, NAOYA HASHIMOTO, JUN-ICHI MORISHIGE, SHOJI FUKUSHIMA, HIROMICHI EBI, KOSAKU UCHIDA, HIROJI IWATA and MASATAKA SAWAKI

Anticancer Research March 2023, 43 (3) 1283-1289; DOI: https://doi.org/10.21873/anticanres.16275
You have access
Risk Factors for Muscle Loss During Neoadjuvant Therapy for Esophageal Cancer
DAISUKE SHIMIZU, KAZUSHI MIYATA, MASAHIDE FUKAYA, SHIZUKI SUGITA and TOMOKI EBATA

Anticancer Research March 2023, 43 (3) 1309-1315; DOI: https://doi.org/10.21873/anticanres.16278
You have access
ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma
DAICHI ENOMOTO, KAZUHIRO YAMAMOTO, YUKI MATSUMOTO, ASAMI MORIOKA, TOMOHIRO OMURA, SHOHEI KOMATSU, YOSHIHIKO YANO, TAKUMI FUKUMOTO and IKUKO YANO

Anticancer Research March 2023, 43 (3) 1317-1323; DOI: https://doi.org/10.21873/anticanres.16279

Main menu

User menu

Search

More articles from Clinical studies

Pages